Dmitry Volkin, MD
Urogynecology and Reconstructive Pelvic Surgery · Waterford, CTNPI 1508203316
Payments from drug & device makers
What this record shows
This record is dominated by grants: $10,516 of the $15,335 with a category attached, or 68.6%. Medtronic accounts for 86.2% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2020 at $10,753 and has fallen 87.5% since, to $1,341 in 2025.
Across 113 payments — averaging $135.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$13K
- Boston Scientific$684
- Coloplast$347
- Astellas Pharma US Inc$241
- Amgen$174
- Axonics, Inc.$161
- plus $503 from 13 others
What the payments were for
- Grants$10,51669%
- Travel & lodging$9436%
- Food & beverage$3,49923%
- Education$3772%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 46 | $13,225 |
| Boston Scientific | 4 | $684 |
| Coloplast | 12 | $347 |
| Astellas Pharma US Inc | 13 | $241 |
| Amgen | 12 | $174 |
| Axonics, Inc. | 3 | $161 |
| AbbVie(2 entities) | 4 | $119 |
| Johnson & Johnson | 5 | $74 |
| Sumitomo Pharma America, Inc. | 2 | $58 |
| Pfizer | 3 | $44 |
| Bard Access Systems, Inc. | 1 | $39 |
| Procept Biorobotics Corporation | 1 | $33 |
| Rochester Medical Corporation | 1 | $30 |
| Hollister Incorporated | 1 | $27 |
| Baxter Healthcare | 1 | $23 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Telix Pharmaceuticals | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$11,264
- GENERAL ERECTILE DYSFUNCTION$516
- Axonics r-SNM System$104
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 323 | $213,111 |
| GemtesaVibegron | 288 | $213,053 |
| Mirabegron ErMirabegron | 26 | $15,201 |
| Estradiol | 152 | $8,520 |
| Tolterodine Tartrate ErTolterodine Tartrate | 28 | $4,295 |
| Solifenacin Succinate | 106 | $3,889 |
| Tamsulosin Hcl | 286 | $3,301 |
| Trospium Chloride ErTrospium Chloride | 28 | $2,991 |
| Methenamine Hippurate | 38 | $1,814 |
| Finasteride | 103 | $1,116 |
| Trospium Chloride | 15 | $1,108 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 131 | $1,069 |
| Fosfomycin Tromethamine | 11 | $997 |
| Trimethoprim | 24 | $979 |
| Oxybutynin Chloride ErOxybutynin Chloride | 46 | $455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $241 | $213,111323 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $58 | $213,053288 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Connecticuton file to place this against a meaningful peer group, so we don't.
Other urogynecology and reconstructive pelvic surgery in Waterford
- Richard KershenHartford$28K
- Oz HarmanliNew Haven$9K
- Elena Tunitsky BittonHartford$9K
- Andrea RussoDanbury$8K
- Elisha JacksonNew Haven$4K
- Mark PrestonWaterbury$2K
- Jaclyn MunozNorwalk$2K
- Elisabeth SappenfieldHartford$2K
- Nancy RingelNew Haven$2K
- Nicole WoodHartford$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.